Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBio The collaboration continues to build
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022(NYSE American: SYN), a diversified
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical
BASEL (dpa-AFX) - Swiss drug major Novartis AG (NVS) announced Monday that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885) did not meet its primary endpoint